MX2012010006A - Agonistas de a3ar para el tratamiento de uveitis. - Google Patents

Agonistas de a3ar para el tratamiento de uveitis.

Info

Publication number
MX2012010006A
MX2012010006A MX2012010006A MX2012010006A MX2012010006A MX 2012010006 A MX2012010006 A MX 2012010006A MX 2012010006 A MX2012010006 A MX 2012010006A MX 2012010006 A MX2012010006 A MX 2012010006A MX 2012010006 A MX2012010006 A MX 2012010006A
Authority
MX
Mexico
Prior art keywords
treatment
uveitis
a3ar agonists
meca
a3ar
Prior art date
Application number
MX2012010006A
Other languages
English (en)
Inventor
Pnina Fishman
Rachel Caspi
Original Assignee
Us Gov Health & Human Serv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Us Gov Health & Human Serv filed Critical Us Gov Health & Human Serv
Publication of MX2012010006A publication Critical patent/MX2012010006A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

La presente descripción se refiere al uso de un agonista de A3AR, tal como IB-MECA, para el tratamiento o prevención de la uveítis en un sujeto, así como también a métodos para el tratamiento y composiciones farmacéuticas que comprenden una cantidad de IB-MECA eficaz para tratar la uveítis.
MX2012010006A 2010-03-03 2011-02-27 Agonistas de a3ar para el tratamiento de uveitis. MX2012010006A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US31004310P 2010-03-03 2010-03-03
PCT/IL2011/000193 WO2011107981A1 (en) 2010-03-03 2011-02-27 A3ar agonists for the treatment of uveitis

Publications (1)

Publication Number Publication Date
MX2012010006A true MX2012010006A (es) 2013-01-17

Family

ID=43867186

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2012010006A MX2012010006A (es) 2010-03-03 2011-02-27 Agonistas de a3ar para el tratamiento de uveitis.

Country Status (9)

Country Link
US (1) US20130045943A1 (es)
EP (1) EP2542242A1 (es)
JP (1) JP2013521274A (es)
KR (1) KR20130072189A (es)
CN (1) CN102905708A (es)
CA (1) CA2790869A1 (es)
MX (1) MX2012010006A (es)
RU (1) RU2012138043A (es)
WO (1) WO2011107981A1 (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3011442A1 (en) * 2016-01-14 2017-07-20 Handok Inc. Compounds antagonizing a3 adenosine receptor, method for preparing them, and medical-use thereof

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5443836A (en) 1993-03-15 1995-08-22 Gensia, Inc. Methods for protecting tissues and organs from ischemic damage
US5688774A (en) 1993-07-13 1997-11-18 The United States Of America As Represented By The Department Of Health And Human Services A3 adenosine receptor agonists
US5773423A (en) 1993-07-13 1998-06-30 The United States Of America As Represented By The Department Of Health And Human Services A3 adenosine receptor agonists
AU1399297A (en) 1996-01-24 1997-08-20 Sumitomo Chemical Company, Limited Dihalopropene compounds, their use as insecticides/acaricides and intermediates for their production
US6048865A (en) 1997-07-29 2000-04-11 Medco Research, Inc. N6 -substituted-adenosine-5'-uronamides as adenosine receptor modulator
CA2296485A1 (en) 1997-07-29 1999-02-11 Medco Research, Inc. N6-substituted-adenosine-5'-uronamides as adenosine receptor modulators
WO1999020284A1 (en) 1997-10-23 1999-04-29 Trustees Of The University Of Pennsylvania Methods for reducing ischemic injury of the heart via the sequential administration of monophosphoryl lipid a and adenosine receptor agents
US6217896B1 (en) 1999-04-01 2001-04-17 Uab Research Foundation Conjunctival inserts for topical delivery of medication or lubrication
IL133680A0 (en) 1999-09-10 2001-04-30 Can Fite Technologies Ltd Pharmaceutical compositions comprising an adenosine receptor agonist or antagonist
US7825102B2 (en) * 2004-07-28 2010-11-02 Can-Fite Biopharma Ltd. Treatment of dry eye conditions
CA2586774A1 (en) * 2004-12-02 2006-06-08 Can-Fite Biopharma Ltd. Treatment of inflammation
JP2009519236A (ja) * 2005-11-30 2009-05-14 キャン−ファイト・バイオファーマ・リミテッド Ａ３アデノシンレセプター抗体の治療的使用

Also Published As

Publication number Publication date
CA2790869A1 (en) 2011-09-09
JP2013521274A (ja) 2013-06-10
CN102905708A (zh) 2013-01-30
WO2011107981A1 (en) 2011-09-09
RU2012138043A (ru) 2014-04-10
KR20130072189A (ko) 2013-07-01
US20130045943A1 (en) 2013-02-21
EP2542242A1 (en) 2013-01-09

Similar Documents

Publication Publication Date Title
MX2015012502A (es) Inhibidores de proteina cinasa dependiente de adn.
UA115983C2 (uk) Інгібітори днк-пк
PH12016500511A1 (en) Selective grp94 inhibitors and uses thereof
IN2015DN01156A (es)
MX2015011898A (es) Compuestos de pirazolo y usos de los mismos.
MX338515B (es) Derivados de tetrahidroquinolina utiles como inhibidores de bromodominio.
MX2015006478A (es) Inhibidores de glutaminasa y metodos de empleo.
MX2015009106A (es) Composiciones de solución sólida y su uso en el tratamiento del dolor intenso.
IN2012DN02735A (es)
IN2012DN02702A (es)
IN2012DN00754A (es)
MY162146A (en) Pharmaceutical composition
MX2011011950A (es) Composiciones de dexmedetomidina sublinguales y metodos de uso de las mismas.
MX2013004061A (es) Analogos de ciclosporina.
MX2016004741A (es) Composicion farmaceutica que comprende un antagonista de trpa1 y un agente analgesico.
NZ702415A (en) Methods for treating neutropenia using retinoid agonists
MX342947B (es) Tratamiento de diabetes tipo 2.
WO2012158672A3 (en) Compounds for use in treatment of mucositis
MX2013004062A (es) Analogos de ciclosporina.
MX366829B (es) Composiciones y formas de dosificacion de itraconazol y metodos de uso de las mismas.
MX2016001104A (es) Composiciones para tratar engrosamiento de la piel.
MX2015001648A (es) Composiciones que comprenden derivados de espicamicina y metodos de uso de los mismos.
MX356102B (es) Compuestos y métodos para tratar leucemia.
MX365285B (es) Complejo lubricante para la boca.
MX2012010006A (es) Agonistas de a3ar para el tratamiento de uveitis.

Legal Events

Date Code Title Description
FA Abandonment or withdrawal